|
1) Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1577-8
|
|
|
|
2) Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007; 30: 1581-3
|
|
|
|
|
|
3) Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combi-nation therapy in patients with essential hyper-tension: the NICE Combi (Nifedipine and Cande-sartan Combination) Study. J Hypertens. 2005; 23: 445-53
|
|
|
|
|
|
4) Fukui T, Rahman M, Hayashi K, et al. Cande-sartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res. 2003; 26: 979-90
|
|
|
|
|
5) JATOS study group. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res. 2005; 28: 513-20
|
|
|
|
|